Why the study?
Venous thromboembolism is the third most common cause of vascular mortality worldwide, prompting a review of how epidemiology and thromboprophylaxis trials shape current prevention approaches.
This review provides a comprehensive overview of modern thromboprophylaxis strategies for preventing venous thromboembolism across diverse patient populations and clinical settings.
Venous thromboembolism (VTE) is the third most common cause of vascular mortality worldwide and comprises deep-vein thrombosis (DVT) and pulmonary embolism (PE). In this review, we discuss how an understanding of VTE epidemiology and the results of thromboprophylaxis trials have shaped the current approach to VTE prevention. We will discuss modern thromboprophylaxis as it pertains to genetic risk factors, exogenous hormonal therapies, pregnancy, surgery, medical hospitalization, cancer, and what is known thus far about VTE in COVID-19 infection.
No takes yet. Share an insight, caveat, or question.
Nicholson et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: